A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Etanercept (ENBREL)

Etanercept suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

First FDA approval2019-06-07
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$5.14B in CY2024 Part D spend630K claims · 105K beneficiaries · 329 plans surveyed

Lowest NADAC
$2076.23/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2080.48
Across all dosage forms in distribution.
Highest NADAC
$2083.35
Range is tight.
Plans with PA
1620 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Etanercept used for?

Etanercept suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

Is there a generic for Etanercept?

No. Etanercept is brand-only with no generic equivalents currently in market.

How much does my plan pay for Etanercept?

Across 329 Part D plans, Etanercept averages $2080.48/unit (NADAC). Lowest available: $2076.23/unit. Highest in distribution: $2083.35/unit.

Is Etanercept on the FDA shortage list?

No. Etanercept is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Tumor Necrosis Factor Blocker6 alternatives in D1
01
Adalimumab-Adaz
Brand: Adalimumab
$1593.32Lowest NADAC
0Generic mfrs
$32.5MCY24 Part D spend
Compare →
02
Adalimumab-Aqvh
Brand: YUSIMRY
$604.15Lowest NADAC
0Generic mfrs
$1.0MCY24 Part D spend
Compare →
03
Adalimumab-Atto
Brand: AMJEVITA
Lowest NADAC
0Generic mfrs
$64.2MCY24 Part D spend
Compare →
04
Adalimumab-Bwwd
Brand: HADLIMA
$611.35Lowest NADAC
0Generic mfrs
$21.4MCY24 Part D spend
Compare →
05
Certolizumab Pegol
Brand: Cimzia
$6072.51Lowest NADAC
0Generic mfrs
$431.9MCY24 Part D spend
Compare →
06
Golimumab
Brand: SIMPONI ARIA
$12974.52Lowest NADAC
0Generic mfrs
$359.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.